FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Salmon Sean

 2. Date of Event Requiring Statement (MM/DD/YYYY)
11/1/2019 

 3. Issuer Name and Ticker or Trading Symbol

Medtronic plc [MDT]

(Last)        (First)        (Middle)

710 MEDTRONIC PARKWAY, LC300

 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP & Group President Diabetes /

(Street)

MINNEAPOLIS, MN 55432      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares 25409 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) 10/28/2020 (2)10/28/2029 Ordinary Shares 14716 $106.22 D  
Stock Option (Right to Buy) 7/30/2013 (2)7/30/2022 Ordinary Shares 21129 $38.81 D  
Stock Option (Right to Buy) 7/30/2013 (2)7/30/2022 Ordinary Shares 2577 $38.81 D  
Stock Option (Right to Buy) 7/29/2014 (2)7/29/2023 Ordinary Shares 14823 $55.32 D  
Stock Option (Right to Buy) 7/29/2014 (2)7/29/2023 Ordinary Shares 1808 $55.32 D  
Stock Option (Right to Buy) 7/28/2015 (2)7/28/2024 Ordinary Shares 13066 $62.76 D  
Stock Option (Right to Buy) 7/28/2015 (2)7/28/2024 Ordinary Shares 1594 $62.76 D  
Stock Option (Right to Buy) 8/3/2016 (2)8/3/2025 Ordinary Shares 17095 $78.00 D  
Stock Option (Right to Buy) 8/3/2016 (2)8/3/2025 Ordinary Shares 1283 $78.00 D  
Stock Option (Right to Buy) 8/1/2017 (2)8/1/2026 Ordinary Shares 15142 $88.06 D  
Stock Option (Right to Buy) 8/1/2017 (2)8/1/2026 Ordinary Shares 1136 $88.06 D  
Stock Option (Right to Buy) 7/31/2018 (2)7/31/2027 Ordinary Shares 27788 $83.97 D  
Stock Option (Right to Buy) 7/31/2018 (2)7/31/2027 Ordinary Shares 1191 $83.97 D  
Stock Option (Right to Buy) 7/30/2019 (2)7/30/2028 Ordinary Shares 25983 $89.08 D  
Stock Option (Right to Buy) 7/30/2019 (2)7/30/2028 Ordinary Shares 1695 $89.08 D  
Stock Option (Right to Buy) 7/29/2020 (2)7/29/2029 Ordinary Shares 21532 $103.26 D  
Stock Option (Right to Buy) 7/29/2020 (2)7/29/2029 Ordinary Shares 1615 $103.26 D  
Stock Option (Right to Buy) 4/30/2013 (2)4/30/2022 Ordinary Shares 4713 $38.20 D  
Stock Option (Right to Buy) 6/29/2018 (3)1/27/2025 Ordinary Shares 16035 $74.84 D  
Explanation of Responses:
(1) Includes grants of restricted stock units which vest on the listed date and for the listed number of shares if the Company's cumulative non-GAAP diluted earnings per share ("EPS") growth measured over the three most recently completed fiscal years exceeds a 3% cumulative compound annual growth rate (as determined by the Compensation Committee): (i) 7,300 restricted stock units that vest on 7/31/2020; (ii) 4,422 restricted stock units that vest on 7/30/2021; and (iii) 5,474 restricted stock units that vest on 7/29/2022.
(2) These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of the grant.
(3) This option became exercisable on June 29, 2018, subject to Medtronic plc's achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Salmon Sean
710 MEDTRONIC PARKWAY
LC300
MINNEAPOLIS, MN 55432

EVP & Group President Diabetes
Signatures
/s/ Perry F. Sekus, attorney-in-fact11/7/2019
**Signature of Reporting PersonDate
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Medtronic Charts.
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Medtronic Charts.